TO THE EDITOR: The article by Hensley et al1 recently published in Journal of Clinical Oncology was interesting, even if apparently negative (Gynecology Oncology Group [GOG]-0277 randomized phase III trial). The study investigated the activity and safety of gemcitabine plus docetaxel followed by doxorubicin versus observation in patients with uterus-limited, highgrade leiomyosarcoma (LMS) in an adjuvant setting. Although the study was closed for accrual futility, available survival results (disease-free survival, overall survival) failed to show better outcomes in the experimental arm. This is probably, for different reasons, the typical study that should not have been started or completed. Adjuvant therapy for early-stage uterine LMS remains controversial, and at the moment, cannot be recommended.

Adjuvant therapy for early uterine high-grade leiomyosarcoma / Tomao, F.; Panici, P. B.; Tomao, S.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 37:11(2019), pp. 935-936. [10.1200/JCO.18.01990]

Adjuvant therapy for early uterine high-grade leiomyosarcoma

Tomao F.
Primo
Writing – Original Draft Preparation
;
Panici P. B.
Penultimo
Visualization
;
Tomao S.
Ultimo
Supervision
2019

Abstract

TO THE EDITOR: The article by Hensley et al1 recently published in Journal of Clinical Oncology was interesting, even if apparently negative (Gynecology Oncology Group [GOG]-0277 randomized phase III trial). The study investigated the activity and safety of gemcitabine plus docetaxel followed by doxorubicin versus observation in patients with uterus-limited, highgrade leiomyosarcoma (LMS) in an adjuvant setting. Although the study was closed for accrual futility, available survival results (disease-free survival, overall survival) failed to show better outcomes in the experimental arm. This is probably, for different reasons, the typical study that should not have been started or completed. Adjuvant therapy for early-stage uterine LMS remains controversial, and at the moment, cannot be recommended.
leiomyosarcoma; oncology; ginecology
01 Pubblicazione su rivista::01f Lettera, Nota
Adjuvant therapy for early uterine high-grade leiomyosarcoma / Tomao, F.; Panici, P. B.; Tomao, S.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 37:11(2019), pp. 935-936. [10.1200/JCO.18.01990]
File allegati a questo prodotto
File Dimensione Formato  
Tomao_Adjuvant-therapy_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 457.29 kB
Formato Adobe PDF
457.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1307285
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact